Inhibition of tumor angiogenesis by the matrix metalloproteinase-activated anthrax lethal toxin in an orthotopic model of anaplastic thyroid carcinoma

Molecular Cancer Therapeutics

Volumn 9, Issue 1, 2010, Pages 190-201

  Alfano, Randall W ^a   Leppla, Stephen H ^b   Liu, Shihui ^b   Bugge, Thomas H ^c   Ortiz, Janelle M ^a   Lairmore, Terry C ^a   Duesbery, Nicholas S ^d   Mitchell, Ian C ^e   Nwariaku, Fiemu ^e   Frankel, Arthur E ^a  

^a TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

^d VAN ANDEL RESEARCH INSTITUTE   (United States)

^e UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRAX TOXIN; B RAF KINASE; GELATINASE; HYBRID PROTEIN; LETHAL FACTOR BETA LACTOSE; LETHAL FACTOR PROTEIN; MATRIX METALLOPROTEINASE; MITOGEN ACTIVATED PROTEIN KINASE; PROTECTIVE ANTIGEN; PROTECTIVE ANTIGEN L1 LETHAL FACTOR HYBRID PROTEIN; SORAFENIB; TUMOR MARKER; UNCLASSIFIED DRUG;

ADVANCED CANCER; ANAPLASTIC CARCINOMA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; CELL SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; ENDOTHELIUM CELL; ENZYME ACTIVATION; ENZYME INHIBITION; FLOW CYTOMETRY; GENE MUTATION; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; LETHAL GENE; MALE; MOUSE; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL TIME; TARGET CELL; THYROID CARCINOMA; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR VASCULARIZATION; WESTERN BLOTTING;

ANIMALS; ANTIGENS, BACTERIAL; BACTERIAL TOXINS; BENZENESULFONATES; CARCINOMA; CELL LINE, TUMOR; CELL PROLIFERATION; ENDOCYTOSIS; HUMANS; MATRIX METALLOPROTEINASES; MICE; MICE, NUDE; MITOGEN-ACTIVATED PROTEIN KINASES; NEOVASCULARIZATION, PATHOLOGIC; PYRIDINES; SURVIVAL ANALYSIS; THYROID NEOPLASMS; TIME FACTORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 73949094858     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-09-0694     Document Type: Article

References (43)

1. Miccoli P, Materazzi G, Antonelli A, Panicucci E, Frustaci G, Berti P. New trends in the treatment of undifferentiated carcinomas of the thyroid. Langenbecks Arch Surg 2007;392:397-404.
2. Xing M. BRAF mutation in thyroid cancer. Endocr Relat Cancer 2007;12:245-62.
3. Wan PT, Garnett MJ, Roe SM, et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004;116:855-67.
4. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417:949-54.
5. Solit DB, Garraway LA, Pratilas CA, et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature 2006;439:358-62.
6. Maeta H, Ohgi S, Terada T. Protein expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinase 1 and 2 in papillary thyroid carcinomas. Virchows Arch 2001;438:121-8.
7. Young JA, Collier RJ. Anthrax toxin: receptor binding, internalization, pore formation, and translocation. Annu Rev Biochem 2007;76:243-65.
8. Abrami L, Liu S, Cosson P, Leppla SH, van der Goot FG. Anthrax toxin triggers endocytosis of its receptor via a lipid raft-mediated clathrin-dependent process. J Cell Biol 2003;160:321-8.
9. Puhar A, Monetcucco C. Where and how do anthrax toxins exit endosomes to intoxicate host cells? Trends Microbiol 2007;15:477-82.
10. Chopra AP, Boone SA, Liang X, Duesbery NS. Anthrax lethal factor proteolysis and inactivation of MAPK kinase. J Biol Chem 2003;278:9402-6.
11. Duesbery NS, Webb CP, Leppla SH, et al. Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor. Science 1998;280:734-7.
12. Duesbery NS, Resau J, Webb CP, et al. Suppression of ras-mediated transformation and inhibition of tumor growth and angiogenesis by anthrax lethal factor, a proteolytic inhibitor of multiple MEK pathways. Proc Natl Acad Sci U S A 2001;98:4089-94.
13. Koo HM, VanBrocklin M, McWilliams MJ, Leppla SH, Duesbery NS, Woude GF. Apoptosis and melanogenesis in human melanoma cells induced by anthrax lethal factor inactivation of mitogen-activated protein kinase kinase. Proc Natl Acad Sci U S A 2002;99:3052-7.
14. Depeille P, Young JJ, Boguslawski EA, et al. Anthrax lethal toxin inhibits growth of and vascular endothelial growth factor release from endothelial cells expressing the human herpes virus 8 viral G protein coupled receptor. Clin Cancer Res 2007;13:5926-34.
15. Abi-Habib RJ, Urieto JO, Liu S, Leppla SH, Duesbery NS, Frankel AE. BRAF status and mitogen-activated protein/extracellular signal-regulated kinase kinase 1/2 activity indicate sensitivity of melanoma cells to anthrax lethal toxin. Mol Cancer Ther 2005;4:1303-10.
16. Abi-Habib RJ, Singh R, Leppla SH, et al. Systemic anthrax lethal toxin therapy produces regressions of subcutaneous human melanoma tumors in athymic nude mice. Clin Cancer Res 2006;12:7437-43.
17. Ding Y, Boguslawski EA, Berghuis BD, et al. Mitogen-activated protein kinase kinase signaling promotes growth and vascularization of fibrosarcoma. Mol Cancer Ther 2008;7:648-58.
18. Liu S, Netzel-Arnett S, Birkedal-Hansen H, Leppla SH. Tumor cell-selective cytotoxicity of matrix metalloproteinase-activated anthrax toxin. Cancer Res 2000;60:6061-7.
19. Alfano RW, Leppla SH, Liu S, Bugge TH, Duesbery NS, Frankel AE. Potent inhibition of tumor angiogenesis by the matrix metalloproteinase-activated anthrax lethal toxin: implications for broad anti-tumor efficacy. Cell Cycle 2008;7:745-9.
20. Alfano RW, Leppla SH, Liu S, et al. Cytotoxicity of the matrix metalloproteinase-activated anthrax lethal toxin is dependent on gelatinase expression and B-RAF status in human melanoma cells. Mol Cancer Ther 2008;7:1218-26.
21. Liu S, Wang H, Currie BM, et al. Matrix metalloproteinase-activated anthrax lethal toxin demonstrates high potency in targeting tumor vasculature. J Biol Chem 2008;283:529-40.
22. Alfano RW, Leppla SH, Liu S, et al. Matrix metalloproteinase-activated anthrax lethal toxin inhibits endothelial invasion and neovasculature formation during in vitro morphogenesis. Mol Cancer Res 2009;7:452-61.
23. Kloos RT, Ringel MD, Knopp MV, et al. Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol 2009;27:1675-84.
24. Hobson JP, Liu S, Rono B, Leppla SH, Bugge TH. Imaging specific cell-surface proteolytic activity in single living cells. Nat Methods 2006;3:259-61.
25. Gupta PK, Moayeri M, Crown D, Fattah RJ, Leppla SH. Role of N-terminal amino acids in the potency of anthrax lethal factor. PLoS One 2008;3:e3130.
26. Kim S, Yazici YD, Calzada G, et al. Sorafenib inhibits the angiogenesis and growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice. Mol Cancer Ther 2007;6:1785-92.
27. Kim S, Park YW, Schiff BA, et al. An orthotopic model of anaplastic thyroid carcinoma in athymic nude mice. Clin Cancer Res 2005;11:1713-21.
28. Searle J, Lawson TA, Abbott PJ, Harmon B, Kerr JF. An electronmicroscope study of the mode of cell death induced by cancerchemotherapeutic agents in populations of proliferating normal and neoplastic cells. J Pathol 1975;116:129-38.
29. Golstein P, Kroemer G. Cell death by necrosis: towards a molecular definition. Trends Biochem Sci 2007;32:37-43.
30. Nikiforova MN, Kimura ET, Gandhi M, et al. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab 2003;88:5399-404.
31. Liu D, Liu Z, Jiang D, Dackiw AP, Xing M. Inhibitory effects of the mitogen-activated protein kinase kinase inhibitor CI-1040 on the proliferation and tumor growth of thyroid cancer cells with BRAF or RAS mutations. J Clin Endocrinol Metab 2007;92:4686-95.
32. Chiacchio S, Lorenzoni A, Boni G, Rubello D, Elisei R, Mariani G. Anaplastic thyroid cancer: prevalence, diagnosis and treatment. Minerva Endocrinol 2008;33:341-57.
33. Liu Z, Hou P, Ji M, et al. Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers. J Clin Endocrinol Metab 2008;93:3106-16.
34. Buergy D, Weber T, Maurer GD, et al. Urokinase receptor, MMP-1 and MMP-9 are markers to differentiate prognosis, adenoma and carcinoma in thyroid malignancies. Int J Cancer 2009;125:894-901.
35. Komorowski J, Pasieka Z, Jankiewicz-Wika J, Stepieñ H. Matrix metalloproteinases, tissue inhibitors of matrix metalloproteinases and angiogenic cytokines in peripheral blood of patients with thyroid cancer. Thyroid 2002;12:655-62.
36. Henderson YC, Ahn SH, Clayman GL. Inhibition of the growth of papillary thyroid carcinoma cells by CI-1040. Arch Otolaryngol Head Neck Surg 2009;135:347-54.
37. Awada A, Hendlisz A, Gil T, et al. Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours. Br J Cancer 2005;92:1855-61.
38. Keating GM, Santoro A. Sorafenib: a review of its use in advanced hepatocellular carcinoma. Drugs 2009;69:223-40.
39. Murphy DA, Makonnen S, Lassoued W, Feldman MD, Carter C, Lee WM. Inhibition of tumor endothelial ERK activation, angiogenesis, and tumor growth by sorafenib (BAY43-9006). Am J Pathol 2006; 169:1875-85.
40. Liu L, Cao Y, Zhang X, et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 2006;66:11851-8.
41. Wilhelm S, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099-109.
42. Warfel JM, Stelle AD, D'Agnillo F. Anthrax lethal toxin induces endothelial barrier dysfunction. Am J Pathol 2005;166:1871-81.
43. Gozes Y, Moayeri M, Wiggins JF, Leppla SH. Anthrax lethal toxin induces ketotifen-sensitive intradermal vascular leakage in certain inbred mice. Infect Immun 2006;74:1266-72.